Related Experiment Video

Updated: Aug 19, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Calcium antagonists: a more expansive role in treating persons with reduced kidney function?

Susanne B Nicholas1, Naureen Tareen, David Martins

  • 1David Geffen School of Medicine at University of California, Los Angeles, CA, USA.

Ethnicity & Disease
|February 24, 2005
PubMed

Insights

Calcium channel blockers (CCB) are increasingly used in chronic kidney disease (CKD) patients. Combining CCB with renin-angiotensin-aldosterone system (RAAS) inhibitors offers a safe and effective approach for managing hypertension in CKD.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Renin-angiotensin-aldosterone system (RAAS) inhibition with diuretics is often the initial therapy for hypertension in chronic kidney disease (CKD).
  • Calcium channel blockers (CCB) were previously less recommended in CKD due to concerns about antiproteinuric effects and renal outcomes compared to RAAS inhibition.

Purpose of the Study:

  • To evaluate the expanded role and efficacy of calcium channel blockers (CCB) in managing hypertension in patients with chronic kidney disease (CKD).
  • To highlight the safety and effectiveness of CCB in combination therapy for difficult-to-treat CKD hypertension.

Main Methods:

  • Review of recent studies on antihypertensive therapies in CKD patients.
  • Analysis of comparative efficacy and safety data for RAAS inhibitors versus CCB.
  • Assessment of combination therapy outcomes involving CCB and RAAS inhibitors.

Main Results:

  • RAAS inhibition with diuretics is a common initial therapy for hypertensive CKD patients.
  • CCB efficacy in reducing proteinuria and composite renal outcomes was considered less than RAAS inhibition.
  • CCB demonstrated safety and efficacy when used in combination with RAAS inhibitors for CKD hypertension.

Conclusions:

  • Despite previous limitations, CCB are finding expanded use in CKD management.
  • Combination therapy with CCB and RAAS inhibitors is crucial for achieving target blood pressures in hypertensive CKD patients.
  • The safety and efficacy profile supports increased utilization of CCB in this population.

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...